Literature DB >> 6713380

Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells.

N W Gibson, L C Erickson, J A Hickman.   

Abstract

L1210 murine leukemia cells were treated in vitro with the novel antineoplastic agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one (M&B 39565), and its interaction with cellular DNA was assessed by alkaline elution. DNA interstrand cross-link and DNA-protein cross-link formation was quantified with regard to drug concentration and length of incubation time after a 2-hr incubation period with drug. Cytotoxicity, as measured by colony formation assays, and DNA damage caused by M&B 39565 were compared with those caused by a breakdown product of M&B 39565, 5-[3-(2-chloroethyl)triazen -1-yl]imidazole-4-carboxamide (MCTIC) and also with 1-(2-chloroethyl)-1-nitrosourea (CNU). Both MCTIC and CNU decompose to yield a 2-chloroethyldiazo species which is capable of alkylating DNA. At equimolar concentrations, all three drugs possessed similar in vitro cytotoxicities; at equitoxic concentrations, they produced similar levels of DNA interstrand cross-linking. The time course for cross-link formation was different for CNU when compared with MCTIC and M&B 39565, with peaks at 6 hr (CNU) and 9 hr (M&B 39565 and MCTIC). This study suggests that M&B 39565 is cytotoxic against L1210 leukemia cells as a consequence of DNA interstrand cross-link formation, probably via its breakdown product MCTIC.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713380

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.

Authors:  H H Fiebig; D P Berger; K Köpping; H C Ottenheijm; Z Zylicz
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma.

Authors:  M Broggini; E Erba; L Morasca; C Horgan; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

Authors:  M McKeage; P Dady; M Clear; A MacDonald
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.

Authors:  M J McKeage; P B Roberts
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

5.  Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.

Authors:  C Goddard; J A Slack; M F Stevens
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

6.  The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.

Authors:  M C Bibby; J A Double; I A Wahed; N Hirbawi; T G Baker
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

7.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

8.  The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of mitozolomide.

Authors:  N W Gibson; L C Erickson
Journal:  Br J Cancer       Date:  1985-08       Impact factor: 7.640

9.  Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism.

Authors:  M J Tisdale
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

10.  Mitozolomide activity on human cancer cells in vitro.

Authors:  E Erba; S Pepe; P Ubezio; A Lorico; L Morasca; C Mangioni; F Landoni; M D'Incalci
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.